risedronic acid has been researched along with Fracture, Pathologic in 49 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In Japan, at present, only weekly alendronate and risedronate, both oral, have been approved for osteoporosis." | 4.85 | [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. ( Okazaki, R, 2009) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| " Also reviewed are results of "bridging" studies designed to demonstrate the comparable efficacy of less frequent dosing regimens to increase bone mineral density and to reduce bone turnover." | 2.45 | Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. ( Bilezikian, JP, 2009) |
| "Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts." | 2.45 | [Risedronate for treatment of osteoporosis]. ( Hagino, H, 2009) |
| "Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures." | 2.44 | Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. ( Iwamoto, J; Matsumoto, H; Takeda, T, 2008) |
| " The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate." | 2.42 | Bisphosphonates: new indications and methods of administration. ( Reid, IR, 2003) |
| "Alendronate has demonstrated significant reductions in vertebral and nonvertebral fracture risk after 3 years." | 2.42 | An approach to postmenopausal osteoporosis treatment: a case study review. ( Kessenich, C, 2003) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| " Strategies to improve adherence to osteoporosis therapy include reducing dosing frequency, changing the route of administration, educating the patient about optimum bisphosphonate administration, and sending patient reminders." | 1.35 | Maximizing effectiveness of bisphosphonate therapy for osteoporosis. ( Martens, MG; Shaw, H, 2008) |
| " Patients remarkably preferred therapy with a proven antifracture efficacy over a dosage frequency." | 1.35 | [Differences among bisfosfonates--specificity of risedronate (Actonel)]. ( Giljević, Z, 2008) |
| "A total of 196 consecutive patients treated for distal radius fractures were included in this study." | 1.35 | Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. ( Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 46 (93.88) | 29.6817 |
| 2010's | 3 (6.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martens, MG | 1 |
| Shaw, H | 1 |
| Giljević, Z | 1 |
| Okazaki, R | 1 |
| Bilezikian, JP | 1 |
| Rozental, TD | 1 |
| Vazquez, MA | 1 |
| Chacko, AT | 1 |
| Ayogu, N | 1 |
| Bouxsein, ML | 1 |
| Hagino, H | 1 |
| Asano, S | 1 |
| Suzuki, A | 1 |
| Itoh, M | 1 |
| Kľoc, P | 1 |
| Tomčovčík, L | 1 |
| Kľoc, J | 1 |
| Ferko, NC | 1 |
| Borisova, N | 1 |
| Airia, P | 1 |
| Grima, DT | 1 |
| Thompson, MF | 1 |
| Borgström, F | 1 |
| Zethraeus, N | 1 |
| Reid, IR | 1 |
| Kessenich, C | 1 |
| Curković, B | 1 |
| Roux, C | 2 |
| Seeman, E | 1 |
| Eastell, R | 1 |
| Adachi, J | 1 |
| Jackson, RD | 1 |
| Felsenberg, D | 1 |
| Songcharoen, S | 1 |
| Rizzoli, R | 1 |
| Di Munno, O | 1 |
| Horlait, S | 1 |
| Valent, D | 1 |
| Watts, NB | 1 |
| Adachi, JD | 1 |
| Bartl, R | 1 |
| Ringe, JD | 1 |
| Christensen, PM | 1 |
| Sørensen, HA | 1 |
| Vestergaard, P | 2 |
| Delmas, PD | 1 |
| McClung, M | 1 |
| Pande, I | 1 |
| Hosking, DJ | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Henderson, S | 1 |
| Hoffman, N | 1 |
| Prince, R | 1 |
| Neumaier, J | 1 |
| Mosekilde, L | 1 |
| Langdahl, B | 1 |
| Briot, K | 1 |
| Trémollières, F | 1 |
| Thomas, T | 1 |
| Brookhart, MA | 1 |
| Avorn, J | 1 |
| Katz, JN | 1 |
| Finkelstein, JS | 1 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Epstein, S | 1 |
| Muschitz, C | 1 |
| Roschger, P | 1 |
| Patsch, J | 1 |
| Pollhammer, I | 1 |
| Koller, B | 1 |
| Klaushofer, K | 1 |
| Resch, H | 1 |
| Iwamoto, J | 1 |
| Matsumoto, H | 1 |
| Takeda, T | 1 |
| Kruse, HP | 1 |
14 reviews available for risedronic acid and Fracture, Pathologic
| Article | Year |
|---|---|
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Admini | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Sp | 2009 |
[Risedronate for treatment of osteoporosis].
Topics: Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Fractures, Bone; Fractures, Spont | 2009 |
[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosph | 2009 |
Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Topics: Aged; Alendronate; Calcium Channel Blockers; Canada; Estrogen Replacement Therapy; Etidronic Acid; F | 2003 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Os | 2003 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement | 2003 |
The use of bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Osteogenesi | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphon | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Dr | 2007 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; | 2007 |
Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Bone Density Conservation Agents; Conf | 2008 |
1 trial available for risedronic acid and Fracture, Pathologic
| Article | Year |
|---|---|
A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; | 2006 |
34 other studies available for risedronic acid and Fracture, Pathologic
| Article | Year |
|---|---|
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; | 2008 |
[Differences among bisfosfonates--specificity of risedronate (Actonel)].
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Fractures, Spontaneo | 2008 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bo | 2009 |
[Osteoporosis management in general practice. Preventing spontaneous bone fractures].
Topics: Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; Fractures, Spo | 2010 |
[Bilateral pathological sub-trochanteric fracture in a long-term biphosphonate user].
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Fractures, Sponta | 2011 |
How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
Topics: Bone Density Conservation Agents; Cost Sharing; Cost-Benefit Analysis; Diphosphonates; Drug Costs; E | 2012 |
[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].
Topics: Aged; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Spo | 2003 |
[For patients with osteoporosis-induced fracture the emergency brake must be pulled. Every 4th patient as a recurrence in the following year].
Topics: Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteop | 2003 |
[Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years].
Topics: Aged; Bone Density; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Spontaneous; Humans | 2003 |
[Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Os | 2003 |
Efficacy of risedronate on clinical vertebral fractures within six months.
Topics: Body Height; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; R | 2004 |
[Consistent therapeutic success in osteoporosis].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; | 2004 |
[Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Aged; Alendronate; Calcitonin; Etidronic | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fr | 2004 |
[Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractu | 2004 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneou | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
[Routine osteoporosis therapy].
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; | 2004 |
[Evaluation of the effects of treatment of osteoporosis].
Topics: Aged; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
[What do we need to know--what can we do?].
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium Channel Blockers; C | 2005 |
[Only bone densitometry answers this question. How stable are your patients' bones?].
Topics: Absorptiometry, Photon; Aged; Bone Density; Diphosphonates; Etidronic Acid; Femoral Neck Fractures; | 2006 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.
Topics: Absorptiometry, Photon; Accidental Falls; Administration, Oral; Biopsy; Bone and Bones; Bone Density | 2007 |
[A new bisphosphonate. A vertebral body fracture seldom remains alone].
Topics: Etidronic Acid; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal | 2000 |
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; | 2001 |
[Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
Topics: Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Follow-Up Stud | 2001 |
[Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].
Topics: Aged; Clinical Trials as Topic; Drug Approval; Etidronic Acid; Female; Femoral Neck Fractures; Fract | 2001 |
[Osteoporosis. Fracture as alarm signal].
Topics: Aged; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenop | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; H | 2001 |
[Therapy of osteoporosis. Risk factors alone are not an indication].
Topics: Aged; Aged, 80 and over; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Oste | 2001 |
[When osteoporosis first manifests itself. Without therapy the next fracture threatens].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; | 2002 |